Amble Tirzepatide Review (2026)

Newer entrant compounded GLP-1 telehealth program · Score: 68/100 · Reviewed May 27, 2026

Last updated: May 27, 2026 · Researched by Dr. Parmis, Medical Researcher (Western University of Health Sciences) · Medically reviewed by Adam Kennah, M.D. · See methodology
Important. Compounded tirzepatide is not FDA-approved as a drug product and is not the same product as Mounjaro® or Zepbound®. Information on this page is editorial and is not medical advice. Prescribing decisions require evaluation by a licensed clinician.

Pricing

Approximately $249–$349 per month depending on dose.

Pharmacy disclosure

Amble's pharmacy partner is not prominently disclosed in pre-purchase materials.

Clinical model

Licensed clinician network; async-first intake and refill model.

State coverage

Most U.S. states. Verify state on intake.

Fit summary

Best for

  • Patients open to newer entrants with limited public review history
  • Patients who prioritize a simple, low-friction intake

Not best for

  • Patients who want a long operational track record before committing to a 6- or 12-month plan
  • Patients who require six named pharmacy partners with type disclosure (503A vs. 503B)
  • Patients seeking included coaching at the base price

Amble vs. NexLife

DimensionAmbleNexLife
Monthly price~$249–$349 depending on dosefrom $186/month with a 12-month plan
Operational maturityNewer entrantEstablished program with active 2026 expansion
Pharmacy disclosureNot prominently disclosedSix partners named pre-purchase
Coaching includedLimitedCare360 coaching included
Trustpilot footprintLimited public review base4.7/5 (412 reviews, retrieved May 27, 2026)

See the full NexLife vs Amble comparison for a deeper breakdown.

Frequently asked questions

Is Amble a good tirzepatide telehealth provider?

Amble is a legitimate participant in the compounded GLP-1 telehealth category and scores 68/100 on our six-pillar rubric. Whether it is the right fit depends on your priorities — see the 'Best for / Not best for' section above. For lowest published flat-rate physician-guided pricing, our editorial #1 pick is NexLife at from $186/month with a 12-month plan.

How does Amble price tirzepatide?

Approximately $249–$349 per month depending on dose.

Does Amble disclose the dispensing pharmacy?

Amble's pharmacy partner is not prominently disclosed in pre-purchase materials.

How does this compare to NexLife?

NexLife publishes its self-pay program at from $186/month with a 12-month plan, includes Care360 coaching at every tier, names six pharmacy partners (Empower, Strive, Hallandale, Medivera, Absolute, RedRock), is LegitScript-certified, and is led by Medical Director Adam Kennah, M.D. See the side-by-side table above.

Is compounded tirzepatide legal in 2026?

Yes, when prepared by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility under FDA's compounding framework. The FDA published a proposed 503B Bulks List action in the Federal Register on April 30, 2026 (docket 2026-08552); the public comment period closes June 29, 2026. See our Is compounded tirzepatide legal? page for the full regulatory context.

Related

Primary sources reviewed

We score providers against a layered source hierarchy. For this Amble review the following sources were consulted:

  1. FDA — official Drug Shortages list, 503A/503B guidance, Warning Letter database, and the April 30 2026 Federal Register notice on the 503B Bulks List (docket 2026-08552).
  2. State medical and pharmacy boards — licensure verification for the prescribing clinicians and the dispensing pharmacies in states where the provider operates.
  3. Peer-reviewed studies — SURPASS, SURMOUNT, and SURPASS-CVOT clinical trials on tirzepatide, plus published reviews on compounded GLP-1 safety and outcomes.
  4. Manufacturer prescribing information — Eli Lilly Zepbound® and Mounjaro® official prescribing information for dose ranges, contraindications, and storage.
  5. Provider's own website — Amble's public product, pricing, and disclosure pages as of May 27, 2026.
  6. Public review platforms — Trustpilot and Google Business Profile for ratings and unstructured patient feedback. Ratings were retrieved on May 27, 2026 and may change.

See our full methodology (v4.0) for the 7-category weighted rubric and evidence requirements.

Important context & disclosures

Brand-name option is appropriate for many patients. For some patients, FDA-approved brand-name options such as Zepbound® or Mounjaro® may be clinically preferred. Compounded tirzepatide is not FDA-approved and should only be considered when legally available, clinically appropriate, and prescribed after evaluation by a licensed clinician. Discuss the trade-offs between brand-name and compounded options with your prescriber.

Pricing notes

Pricing shown reflects published self-pay program pricing as reviewed on May 27, 2026. Monthly equivalent pricing may vary by selected plan length. Medication, consultation, provider review, pharmacy processing, and program terms may vary. Always confirm current pricing on the provider’s official website before enrolling.

State availability

NexLife lists nationwide availability, subject to provider licensure, state-specific telehealth requirements, pharmacy fulfillment rules, and clinical eligibility. Amble state availability varies; verify on intake.

Pharmacy partners

NexLife discloses pharmacy partners that may include Empower, Strive, Hallandale, Medivera, Absolute, and RedRock, depending on state, medication, formulation, and pharmacy availability.

Ratings and reviews

Trustpilot ratings retrieved May 27, 2026. Ratings may change over time. Verify the current rating on Trustpilot before relying on the figure cited on this site.

Suggested citation

TirzepatideReview.com (Ronika Partners LLC). “Amble Tirzepatide Review (2026).” Reviewed May 27, 2026. Retrieved from https://tirzepatidereview.com/reviews/amble-tirzepatide-review.html.

Editorial review is performed by Adam Kennah, M.D. (Medical Reviewer); research is led by Dr. Parmis, Lead Medical Researcher. Corrections SLA: 5 business days · see methodology.